Jim Corbett this morning on the Bell Potter healthcare conference has confirmed profitability guidance by Q3 2025. Record sales for the current Qtr coming up guidance between 22-24 US Million.
The big news is the addition of Cohealyx dermal matrix (if approved), with Permeaderm and ReCell would increase the TAM from a burn patient with 20 per cent bun from US 13,000 to US 28,000 this is a huge step up and if approved this will be a large driver of revenue.
He also confirmed that sales team of 58 is sufficient to cover all the US target hospitals and no plans to increase this in the next 24months.
Costs will come down this qtr - confirmed by CFO on last weeks investor conference, and explained that there were one off costs last Qtr that are non recurring.
THE WRITING IS ON THE WALL.
AVH Price at posting:
$3.64 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)